Alzheimer's Disease Trial, Recruiting NCT06565143 Sponsor: Anhui Medical University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06565143
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with early Alzheimer's disease or a related condition, based on recognised international diagnostic guidelines.
  • People whose memory and thinking test score (called an MMSE) falls between 10 and 27, which indicates mild to moderate difficulties with memory or thinking.
  • People whose disease severity rating (called a CDR score) is 2 or below, meaning the condition is not at its most advanced stage.
  • People who have been taking a specific type of Alzheimer's medication called a cholinesterase inhibitor (IAChE) for at least 3 months.
  • People who take medications for mood or mental health may still be considered, as long as those medications have been taken at the same dose for at least 3 months.

Who may not be able to join:

  • People whose disease severity rating (CDR score) is higher than 2, meaning the condition is at a more advanced stage.
  • People with a history or current signs of other serious mental health conditions, such as major depression, psychosis, or obsessive-compulsive disorder.
  • People with a history of head injury, stroke, or other conditions affecting the brain or nervous system.
  • People whose brain scans show structural abnormalities in the brain.
  • People with a history of seizures or episodes of unexplained loss of consciousness.
  • People who have an implanted medical device such as a pacemaker, medication pump, vagal nerve stimulator, or deep brain stimulator.
  • People with a family history of epilepsy that has not responded to medication.
  • People who have had issues with substance misuse within the last 6 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-0551-62922263

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Anhui Medical University
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
1 March 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Alzheimers Disease Assessment Scale Cognitive section(ADAS-Cog)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov